Metabolic Adverse Effects of Low-Dose Quetiapine: A Systematic Review and Meta-Analysis.

Acta Psychiatr Scand

RISE-Health, Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Porto, Portugal.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: The use of off-label, low doses of second-generation antipsychotics (SGAs), in particular quetiapine, has risen significantly. SGAs are known to cause metabolic adverse effects, including weight gain. The aim of this systematic review and meta-analysis was to assess the impact of low-dose quetiapine on metabolic outcomes, such as weight, glycemic, and lipid metabolism.

Methods: Following the PRISMA statement, PubMed, Web of Science Core Collection, Cochrane Library, ClinicalTrials.gov, Google Scholar, and PsycINFO were systematically searched for randomized controlled trials > 4 weeks, reporting metabolic outcomes of quetiapine < 200 mg. RoB2 was used to assess bias. SPSS was used for quantitative data management and aggregation.

Results: Eight unique studies (n = 3085) were included, six of which were included in the meta-analysis. Low doses of quetiapine led to significant weight gain (mean difference [MD] = 0.58 kg, 95% CI: 0.32-0.83) and HDL cholesterol reduction (MD = -1.25 mg/dL, 95% CI: -1.86 to -0.65). Patients gaining ≥ 7% of baseline weight was 2.12 times more likely to have taken quetiapine.

Conclusion: Despite limited generalizability, these findings suggest that, even at low doses, quetiapine has an impact on metabolism. Further research is needed to clarify its role in metabolic dysregulation. This study was registered in the international database of prospectively registered systematic reviews (PROSPERO CRD420250588527).

Download full-text PDF

Source
http://dx.doi.org/10.1111/acps.70023DOI Listing

Publication Analysis

Top Keywords

metabolic adverse
8
adverse effects
8
low-dose quetiapine
8
systematic review
8
review meta-analysis
8
metabolic outcomes
8
metabolic
4
effects low-dose
4
quetiapine
4
quetiapine systematic
4

Similar Publications

Pomegranate (Punica granatum L) is a rich source of bioactive compounds, including punicalagin, ellagic acid, anthocyanins, and urolithins, which contribute to its broad pharmacological potential. This review summarizes evidence from in vitro and in vivo experiments, as well as clinical studies, highlighting pomegranate's therapeutic effects in inflammation, metabolic disorders, cancer, cardiovascular disease, neurodegeneration, microbial infections, and skin conditions. Mechanistic insights show modulation of pathways such as nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK), alpha serine/threonine-protein kinase (AKT1), and nuclear factor erythroid 2-related factor 2 (Nrf2).

View Article and Find Full Text PDF

In Brief: Advanced maternal age (AMA) is associated with adverse pregnancy outcomes, particularly those associated with placental dysfunction. This study showed that in a mouse model of AMA, male but not female fetuses had increased placental apoptosis and lipid peroxidation, as well as increased mitochondrial content, suggesting that the placentas of male fetuses in AMA mothers adapt to be able to deliver sufficient energy to the fetus.

Abstract: Although advanced maternal age (AMA) increases the risk of fetal growth restriction (FGR) and stillbirth, the mechanisms leading to the placental dysfunction observed in AMA are unknown.

View Article and Find Full Text PDF

This study investigates the interaction between circadian rhythms and lipid metabolism disruptions in the context of obesity. Obesity is known to interfere with daily rhythmicity, a crucial process for maintaining brain homeostasis. To better understand this relationship, we analyzed transcriptional data from mice fed with normal or high-fat diet, focusing on the mechanisms linking genes involved with those regulating circadian rhythms.

View Article and Find Full Text PDF

Background: Statin therapy lowers the risk of major adverse cardiovascular events (MACE) among people with HIV (PWH). Residual risk pathways contributing to excess MACE beyond low-density lipoprotein cholesterol (LDL-C) are not well understood. Our objective was to evaluate the association of statin responsive and other inflammatory and metabolic pathways to MACE in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

View Article and Find Full Text PDF

Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.

Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.

View Article and Find Full Text PDF